-
Product Insights
NewPulmonary Hypertension – Drugs In Development, 2024
Empower your strategies with our Pulmonary Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary hypertension (PH) is a rare condition marked by high blood pressure in the pulmonary arteries, which supply blood to the lungs. It can stem from various causes, including heart or lung diseases. PH leads to arterial narrowing, forcing the heart to work harder, potentially resulting in heart failure. Common symptoms include breathlessness, fatigue, chest pain, and dizziness. Management involves medication, oxygen...
-
Product Insights
NewUveal Melanoma – Drugs In Development, 2024
Empower your strategies with our Uveal Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Uveal melanoma, the most common intraocular tumor, is a disease in which malignant (cancer) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include a dark spot on the iris, glaucoma, eye pain, and eye redness. Uveal melanoma is more common...
-
Product Insights
NewNet Present Value Model: Galectin Therapeutics Inc’s Belapectin
Empower your strategies with our Net Present Value Model: Galectin Therapeutics Inc's Belapectin report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belapectin in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belapectin in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belapectin in Non-Small Cell Lung Cancer Drug Details: Belapectin (GR-MD-02)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYT-200 in Urethral Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LYT-200 in Urethral Cancer Drug Details: LYT-200 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belapectin in Portal Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belapectin in Portal Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belapectin in Portal Hypertension Drug Details: Belapectin (GR-MD-02) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emraclidine in Psychosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Emraclidine in Psychosis Drug Details: Emraclidine (CVL-231) is under development for the treatment of schizophrenia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efineptakin Alfa in Gastrointestinal Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efineptakin Alfa in Gastrointestinal Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efineptakin Alfa in Gastrointestinal Tract Cancer Drug Details: Efineptakin alfa...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Navicixizumab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Navicixizumab in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Navicixizumab in Gastric Cancer Drug Details:Navicixizumab (OMP-305B83) is under development for the treatment...